Alzheimer’s disease or a new antibody therapy — science and technology

Alzheimer’s disease or new antibody therapy — technology — original title: Alzheimer’s disease or a new antibody therapy technology daily August 31 Beijing Xinhua (reporter Zhang Mengran) a neurodegenerative disease research published this week publication of the British "nature" magazine showed that an antibody therapy can reduce the brain of patients with Alzheimer’s disease in the light beta amyloid plaques. The study provides preclinical data and preliminary results of phase I clinical trials, two of which support further development of the antibody for the treatment of Alzheimer’s disease. Amyloid accumulation in the brain is a marker of Alzheimer’s disease. It is generally believed that beta amyloid toxicity caused by synaptic dysfunction and neurodegeneration, the two will cause the onset of Alzheimer’s disease, but the clinical therapy for beta amyloid protein has not been successful. The researchers, Biogen Alfred famous American biotechnology company? Sangduoke and colleagues report the development of a human monoclonal antibody Aducanumab, which is determined by the drug therapy of Alzheimer’s disease 100 healthy development, can be selectively targeted to amyloid beta protein, known as the "new hope against Alzheimer’s disease". Now, the researchers said, in a genetically modified mouse model, "Aducanumab" can enter the brain, dose dependent reduction of soluble and insoluble beta amyloid protein. The author also carried out a randomized double-blind placebo-controlled phase I clinical trial, to evaluate each month to have mild cognitive impairment or mild dementia and memory in brain beta amyloid deposits in Alzheimer’s disease patients with injection of "Aducanumab" after the presentation of safety and tolerability. Over the course of 1 years, a total of 165 patients received a placebo or Aducanumab". After 54 weeks of treatment, patients with "Aducanumab" had a significantly reduced beta amyloid protein in the brain, and the higher the dose, the greater the extent of plaque reduction. There were 40 patients who discontinued treatment during the period, including 20 patients with adverse reactions, including dose dependent amyloid imaging. In this article, the authors conclude that the identification of anti beta amyloid therapies that can slow cognitive decline will revolutionize the way we understand, treat and prevent Alzheimer’s disease. (commissioning editor Wei Yan and Zhao Zhuqing)相关的主题文章: